C-IBLXAmplifier Therapeutics
AMPK activation, metabolic switching
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IBLX
C-IBLXC-IBLXAMPK activation, metabolic switching
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Amplifier Therapeutics AMPK activation, metabolic switching
Amplifier Therapeutics describes its work as harnessing AMPK activation to address metabolic disease. The site states that AMPK signaling decreases with age and links reduced AMPK activation to chronic aging-related diseases caused by dysfunctional metabolism. Its listed program includes ATX-304, with featured publications and presentations on MASLD, semaglutide combination data, and cisplatin-induced acute kidney injury.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Amplifier Therapeutics — Translational · Lower middle. Derived deterministically from 1 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic